High-level tissue-specific expression of functional human factor VIII in mice

Area of Science:

• Gene Therapy
• Hematology
• Molecular Biology

Background:

• Hemophilia A is caused by low levels of factor VIII (FVIII), making it a target for gene therapy.
• Previous adenoviral vectors showed high FVIII expression but faced challenges with mRNA accumulation and protein stability.
• Gene therapy aims to restore FVIII levels for treating Hemophilia A.

Purpose of the Study:

• To develop an improved adenoviral vector for enhanced FVIII expression in Hemophilia A gene therapy.
• To investigate the impact of an intronic sequence on FVIII expression from an adenoviral vector.
• To assess the feasibility of liver-specific FVIII expression using a targeted promoter.

Main Methods:

• Generation of a second-generation FVIII adenoviral vector (Av1ALAPH81) incorporating an intron.
• Administration of Av1ALAPH81 and a previous vector (Av1ALH81) to mouse models.
• Quantification of plasma FVIII levels using established assays.
• Evaluation of vector dose-response and liver-specific expression using a liver-specific promoter.

Main Results:

• The intron-containing vector Av1ALAPH81 significantly increased FVIII plasma levels in mice (1,046 ng/ml) compared to the previous vector (307 ng/ml).
• Therapeutic FVIII levels (10-200 ng/ml) were achieved with lower, less toxic doses of the enhanced vector.
• Adenoviral-mediated FVIII expression was successfully targeted to the liver using a liver-specific promoter.

Conclusions:

• The enhanced adenoviral vector Av1ALAPH81 demonstrates superior efficacy for FVIII expression in Hemophilia A gene therapy.
• This improved vector allows for lower, safer doses while maintaining high therapeutic FVIII levels.
• Liver-specific FVIII expression is achievable, representing a critical step towards regulated gene therapy for Hemophilia A.